Susan Bal

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma

Luciano J. Costa, Saurabh Chhabra, Eva Medvedova et al. · Journal of Clinical Oncology · 2021 · 238 citations

Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial

Luciano J. Costa, Saurabh Chhabra, Eva Medvedova et al. · The Lancet Haematology · 2023 · 133 citations · Full text

Hematological Malignancy, Oncology, Final Report +9

Recommendations on prevention of infections during chimeric antigen receptor <scp>T</scp>‐cell and bispecific antibody therapy in multiple myeloma

Meera Mohan, Rajshekhar Chakraborty, Susan Bal et al. · British Journal of Haematology · 2023 · 60 citations · Full text

BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study

Susan Bal, Myo Htut, Omar Nadeem et al. · Blood · 2023 · 55 citations

Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials

Saurabh Chhabra, Natalie S. Callander, Nicole Watts et al. · Transplantation and Cellular Therapy · 2022 · 53 citations · Full text